Grantham, Mayo, Van Otterloo & Co (GMO)
PTGX icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Protagonist Therapeutics PTGX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-18,300
Closed -$129K – 819
2020
Q1 		$129K Sell
18,300
-1,700
-9% -$12.7K ﹤0.01% 723
2019
Q4 		$141K Sell
20,000
-18,400
-48% -$183K ﹤0.01% 664
2019
Q3 		$461K Buy
+38,400
New +$484K ﹤0.01% 637

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s PTGX Position: Q2 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Protagonist Therapeutics (PTGX) in Q2 2020, closing a stake of 18,300 shares — an estimated $129K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in PTGX in Q3 2019 and held it in 3 quarters. The position peaked at $461K in Q3 2019. 85 funds tracked by Wall St. Rank hold PTGX as of Q2 2020.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Protagonist Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 18,300 Protagonist Therapeutics shares in Q2 2020, an estimated $129K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Protagonist Therapeutics in Q3 2019 and held it in 3 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Protagonist Therapeutics position peaked at $461K in Q3 2019.
  • 85 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2020, filed 13 Aug 2020.